Century Therapeutics Inc. came out of stealth mode Monday with $250 million in funding commitments from lead investor Bayer AG, founding investor Versant Ventures and strategic partner Fujifilm Holdings Corp. to develop next-generation allogeneic cell therapies for cancer, based on induced pluripotent stem cells (iPSCs). Read More
Korea's largest pharmaceutical company, Yuhan Corp., and German giant Boehringer Ingelheim GmbH (BI) have signed a collaboration and license agreement to develop a first-in-class dual agonist to treat nonalcoholic steatohepatitis (NASH) and related liver diseases, following a similar path trod by other companies. Read More
Adding I.V. sildenafil – the active ingredient in Viagra – to inhaled nitric oxide (iNO) therapy for newborns with persistent pulmonary hypertension (PPHN) failed to achieve a statistically significant reduction in treatment failure rates or time on iNO vs. iNO alone in the first part of a phase III study sponsored by Pfizer Inc. Read More
The industry is again preparing for a no-deal Brexit, as political shifts indicate that the U.K. crashing out of the EU on Oct. 31 is an increasingly likely outcome. Read More
The Warburg effect – the marked preference of tumors for fueling themselves via anaerobic metabolism – was described more than 90 years ago. Otto Warburg won the Nobel Prize for his discovery in 1931, and research into the phenomenon long dominated the field of tumor metabolism. Over the past decade, however, there has been increased attention to the fact that tumor metabolism is deregulated in multiple ways beyond the Warburg effect. Read More
FDA clearance of Retrophin Inc.'s enteric-coated (EC) version of Thiola (tiopronin) 100-mg and 300-mg tablets for cystinuria – a rare, inherited disorder that causes levels of cystine to build up in urine, which leads to recurrent kidney stones – gave patients new dosing flexibility and set Wall Street abuzz about options for the San Diego-based firm as well. Read More
The ultimate vision is pretty fantastical: A variety of synthetically engineered bacteria working together to diagnose – and even secrete proteins to treat – various inflammatory conditions or other immune-associated diseases. But researchers at the Wyss Institute at Harvard University and Harvard Medical School have taken another step along the path toward that goal. Read More
Shares of San Diego-based Atyr Pharma Inc. (NASDAQ:LIFE) rose 6.3% to $5.45 on the company's first full day of trading following a 1-for-14 reverse split of its common stock that helped the company regain compliance with the Nasdaq minimum bid price requirement. Read More
CNS Pharmaceuticals Inc., of Houston, filed an S-1 with the SEC for a proposed IPO to raise about $10 million by offering 2.1 million shares priced at $4 to $5 per share. Founded in 2017, CNS Pharmaceuticals is developing therapies for brain cancer and other central nervous system tumors. It is seeking a listing on Nasdaq under the ticker CNSP. Read More
